Professor Jane Armitage
Websites
-
University of Cambridge
Chair of INTERVAL Trial Steering Committee
-
University of Cambridge
Chair of RITARAZEM Trial Steering Committee
-
University of Cambridge
Independent Member of AdDIT Trial Steering Committee
-
University of Kelaniya
Clinical Trials Unit Scientific Advisory Board
Jane Armitage
FRCP, FFPH
Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Jane Armitage is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine. In addition, she is Director of Training and Career Development for the Nuffield Department of Population Health.
She joined the Clinical Trial Service Unit, now part of NDPH, in 1990 having qualified in clinical medicine in 1979. She worked in a variety of specialties over several years with particular experience in respiratory medicine, geriatrics and diabetes. Since joining CTSU she has co-ordinated and been chief investigator for a series of large-scale randomised clinical trials in cardiovascular disease including the 20,000 participant MRC/BHF Heart Protection Study, the 12,000 patient SEARCH and 25,000 HPS2-THRIVE study, which are trials of lipid modification in people with or at risk of vascular disease. In addition she is Chief Investigator for the BHF-supported ASCEND trial of aspirin and fish oils involving 15,000 people diabetes. She collaborates with other epidemiologists and statisticians in NDPH on a variety of genetic and other risk factor studies based on the trial cohorts. She also continues a clinical role in the Lipid Clinic at the Oxford University Hospital NHS Trust and has a particular interest in the safety of statins. Her main research interests are in lipids and the epidemiology of cardiovascular and other chronic diseases including osteoporosis.
Recent publications
Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes.
Journal article
Madurasinghe VW. et al, (2026), Trials, 27
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Journal article
Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists' (CTT) Collaboration ., (2026), Lancet
Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in England.
Journal article
Kaptoge S. et al, (2026), Lancet Haematol, 13, e64 - e73
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Journal article
Scotland G. et al, (2025), Diabet Med, 42
Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.
Journal article
Hammami I. et al, (2025), Heart, 111, 716 - 721
